Morgan Stanley initiated coverage of MapLight Therapeutics (MPLT) with an Overweight rating and $34 price target The company’s lead asset, ML007-C-MA, has “best in class potential” in the greater than $20B market for antipsychotics, the analyst tells investors in a research note. The firm says approved antipsychotics are all very similar, with high switch rates, positioning novel drug mechanisms to gain market share.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MPLT: